MannKind finalizes purchase of scPharmaceuticals

Written by Emily J. Thompson, Senior Investment Analyst

SCPH%

MNKD-6.63%

Updated: Oct 07 2025

0mins

Acquisition Details: MannKind Corporation has completed the acquisition of scPharmaceuticals, which is expected to enhance its revenue growth through the innovative therapy FUROSCIX for edema related to chronic heart failure and kidney disease.
Financial Implications: The acquisition, structured as a tender offer at $5.35 per share plus contingent value rights, positions MannKind for an annualized revenue run rate exceeding $370 million by Q2 2025, bolstered by its existing commercial assets.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

MannKind finalizes purchase of scPharmaceuticals

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

IBM Stock Soars 35% in 2025, Driven by AI Business Growth

Critical Metals Corp. Forms $1.5 Billion Joint Venture for Rare Earth Processing in Saudi Arabia

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch